• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

606
23
13
13
12

COUNTRY

12
7
4
3
2

PRICE

537
587
612
869

PUBLISHED

6
30
122
869

PRODUCT TYPE

486
382
1

Immune Disorders

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

Ragweed Allergy - Pipeline Review, H2 2013

Ragweed Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Ragweed Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

November 2013
FROM

Auto Inflammatory Disease - Pipeline Review, H2 2013

Auto Inflammatory Disease - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Auto Inflammatory Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

November 2013
FROM

Grass Pollen Allergy - Pipeline Review, H2 2013

Grass Pollen Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Grass Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

November 2013
FROM

Kidney Transplantation Global Clinical Trials Review, H2, 2013

Kidney Transplantation Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Kidney Transplantation Global Clinical Trials Review, H2, 2013" provides data on the Kidney Transplantation...

November 2013
FROM

Liver Transplantation Global Clinical Trials Review, H2, 2013

Liver Transplantation Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Liver Transplantation Global Clinical Trials Review, H2, 2013" provides data on the Liver Transplantation...

November 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 Summary The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s...

October 2013
FROM

Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

Orencia (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Orencia (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis...

October 2013
FROM

Benlysta (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Benlysta (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Italy Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Spain Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - UK Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Japan Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM
Loading Indicator

Our Clients

Our clients' logos